78. 下垂体前葉機能低下症 Hypopituitarism Clinical trials / Disease details

臨床試験数 : 494 / 薬物数 : 385 - (DrugBank : 49) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 100

diseases per page:

Showing 1 to 10 of 494 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04867317 (ClinicalTrials.gov)	March 1, 2022	8/4/2021	AGH Replacement Therapy With mTBI	CSP #2018 - Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) a ...	Adult Growth Hormone Deficiency;Mild Traumatic Brain Injury	Drug: Somatropin;Other: Placebo	VA Office of Research and Development	NULL	Not yet recruiting	21 Years	55 Years	All	172	Phase 3	United States
2	NCT05250063 (ClinicalTrials.gov)	February 18, 2022	10/2/2022	Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial LUM-201-01 T ...	A Multicenter, Open-Label, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Month ...	Growth Hormone Deficiency	Drug: LUM-201	Lumos Pharma	NULL	Enrolling by invitation	3 Years	13 Years	All	20	Phase 2	United States
3	NCT05230550 (ClinicalTrials.gov)	February 3, 2022	28/1/2022	Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®	Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® A Mult ...	Adult Growth Hormone Deficiency	Drug: Somapacitan	Novo Nordisk A/S	NULL	Enrolling by invitation	N/A	N/A	All	200		Japan
4	EUCTR2020-000929-42-BG (EUCTR)	07/01/2022	20/01/2021	Trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily s ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth Hormone Deficiency(AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;Te ...	Product Name: lonapegsomatropin drug product Product Code: ACP-011 INN or Proposed INN: LONAPEGSOMATROP ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Israel;Italy;France;Australia;Denmark;Net ...
5	NCT05171855 (ClinicalTrials.gov)	December 16, 2021	24/9/2021	A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Horm ...	A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegso ...	Adult Growth Hormone Deficiency;Endocrine System Diseases;Hormone Deficiency	Drug: Lonapegsomatropin	Ascendis Pharma Endocrinology Division A/S	NULL	Recruiting	23 Years	81 Years	All	240	Phase 3	United States
6	JPRN-jRCT2031210366	15/11/2021	05/10/2021	An extension study of phase 2 study of JR-142 in pediatric patients with growth hormone deficiency	An extension study of phase 2 study of JR-142 in pediatric patients with growth hormone deficiency	Growth hormone deficiency in children	[Investigational product] JR-142 0.75 mg/kg/week or 0.5 mg/kg/week, weekly subcutaneous injection [Com ...	Ioroi Minoru	NULL	Not Recruiting	Not applicable	Not applicable	Both	24	Phase 2	Japan
7	EUCTR2020-000929-42-IT (EUCTR)	18/10/2021	08/06/2021	Trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily s ...	foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-c ...	Adult Growth Hormone Deficiency(AGHD) MedDRA version: 20.0;Level: PT;Classification code 10056438;Te ...	Product Name: lonapegsomatropin drug product Product Code: [ACP-011] INN or Proposed INN: lonapegsomatr ...	Ascendis Pharma Endocrinology Division A/S	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Israel;Italy;France;Australia;Denmark;Net ...
8	NCT05188131 (ClinicalTrials.gov)	October 1, 2021	1/12/2021	Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium	Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium	Hypopituitarism	Drug: Intravenous Infusion of Diclofenac Sodium;Drug: Intravenous Infusion of Placebo	Azienda Ospedaliera Città della Salute e della Scienza di Torino	NULL	Completed	20 Years	50 Years	All	12	Phase 4	Italy
9	NCT04897802 (ClinicalTrials.gov)	September 13, 2021	17/5/2021	Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)	Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Place ...	Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolatio ...	Drug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administration	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Instituto de Salud Carlos III	Recruiting	18 Years	65 Years	All	52	Phase 4	Spain
10	NCT04786873 (ClinicalTrials.gov)	September 2021	3/3/2021	A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone ...	Multicenter, Open Label Trial to Investigate the Efficacy and Safety of a Single Oral Dose of 1.0 mg ...	Growth Hormone Deficiency	Drug: Macimorelin;Diagnostic Test: Arginine;Diagnostic Test: Clonidine	AEterna Zentaris	Novo Nordisk A/S	Recruiting	2 Years	17 Years	All	100	Phase 3	United States

First Previous1 2 3 4 5…50Next Last